Critical appraisal:Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al 2012 2
From Cancer Guidelines Wiki
Risk of bias assessment: randomised controlled trial
Was the trial double-blinded?
- Outcomes not blinded, substantial side-effects, or not reported.
Was the treatment allocation schedule concealed?
- No concealment or unclear (e.g. no approach described, open randomisation lists, person doing recruitment tossing a coin).
Were all randomised participants included in the analysis?
- No exclusions or survival analysis used with all subjects included (>95% follow-up for all groups).
The field below is not considered when calculating the risk of bias rating
Overall risk of bias
| High risk of bias | Additional comments: trial was not blinded and did not describe treatment allocation, intention to treat population |
This appraisal has been completed.
- Article
- Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012 Jul 12;367(2):107-14 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22663011.
- Assigned to
- User:Cecilia.taing
- Topic area
- Guidelines:Melanoma
- Clinical question
Section below only relevant for Cancer Council Project Officer